AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02766361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
Study NCT00862732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
Study NCT00764907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: Given IV during reinduction
Study NCT03821623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
Study NCT03821623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo pills twice a day for 3 months
Study NCT00306644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: study drug
Study NCT01990456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHASE 1: impact of tidal ventilation on VILI
Description: PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
Study NCT01990456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHASE 2: impact of PEEP on VILI
Description: PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
Study NCT01735071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and trabectedin
Description: Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
Study NCT01735071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, trabectedin and carboplatin
Description: Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days
Study NCT03867019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability parameters monitoring
Description: No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)
Study NCT00357656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Description: An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always >= 0.4 mL/h.
Study NCT00357656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Description: The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
Study NCT03623178 — intervention group
Intervention type: OTHER
Intervention: Assertive Community Treatment
Description: The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
Study NCT03623178 — intervention group
Intervention type: OTHER
Intervention: Treatment As Usual
Description: The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
Study NCT01656629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20 mcg subq daily for 3 months
Study NCT01656629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg weekly for 3 months
Study NCT01656629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium and vitamin D
Study NCT02776033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Study NCT03763942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMindr App
Description: Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
Study NCT03763942 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control App
Description: Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
Study NCT01807442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview and Adherence
Description: All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
Study NCT02987205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra
Description: NLF correction
Study NCT02987205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: NLF Correction
Study NCT02335164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax2
Description: Delta inulin adjuvant formulation 2
Study NCT02145429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving therapy and Brief Behavioral Treatment of Insomnia
Description: Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services.
Study NCT04998175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventriculo-peritoneal shunt
Description: A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
Study NCT01143116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver-nitrate coated catheter (Catheter A)
Description: Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
Study NCT01143116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Degradable silver particle-coated catheter (Catheter B)
Description: Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
Study NCT00850629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimodal lifestyle intervention
Description: After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
Study NCT00850629 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention, only follow up
Study NCT01070186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg/day for 4 weeks
Study NCT01070186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Conducted prior to administration of sunitinib therapy
Study NCT01070186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Nephrectomy 2-4 weeks after last dose of Sunitinib
Study NCT01070186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers
Description: Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib
Study NCT02883010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Softport V1.6
Description: PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
Study NCT02883010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Care path normally used by the hospital
Study NCT04057313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee
Description: Coffee used will be the boiled unfiltered Arabica coffee
Study NCT04057313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coffee
Description: Coffee used will be the boiled unfiltered Arabica coffee
Study NCT00125138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone HCl
Description: 20 mg/day. Strength of melperone syrup is 5 mg/mL
Study NCT00125138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone HCl
Description: 40 mg/day. Strength of melperone syrup is 5 mg/mL
Study NCT00125138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone HCl
Description: 60 mg/day. Strength of melperone syrup is 5 mg/mL
Study NCT00125138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Syrup formulation
Study NCT02776904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immediate Post-concussion Assessment and Cognitive Testing
Description: Computerized assessment that provides information related to visual reaction time and visual memory.
Study NCT02776904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gait with single and dual task
Description: Walking alone and then walking while performing a memory task on a tablet.
Study NCT02776904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Y-Balance test
Description: Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
Study NCT03929718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: receive spironolactone treatment after CTI ablation
Study NCT03929718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Spironolactone
Description: no spironolactone treatment
Study NCT02975219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: 4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
Study NCT00773474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
Study NCT02897518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imago V-Balde
Description: the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
Study NCT02897518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
Study NCT03945474 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: See description in sham arm.
Study NCT03945474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation, OMT
Description: See description in OMT arm
Study NCT01679379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable suture group
Description: Skin is closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\]
Study NCT01679379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non absorbable suture group
Description: Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
Study NCT04142021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography
Description: Surgery planning done based solely on coronary computed tomography angiography.
Study NCT04164615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB221
Description: GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.
Study NCT04164615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.
Study NCT02877823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Healthy Lifestyle Education, bottled water, pedometer, family navigator service
Study NCT02877823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Healthy Lifestyle Education
Study NCT01730209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus once daily titrated to trough levels of 5-10 ng/ml.
Study NCT01730209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04760366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial- muscular lengthening therapy
Description: Patients in this group will receive interventional therapy~To perform this technique:~1. Have the patient in side lying position~2. Hip is maximally flexed to shorten the iliopsoas muscle.~3. Therapist fingers should be on to the targeted area.~4. Apply gentle pressure in upward direction.~5. While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~6. Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~   * Hot pack for 15 minutes.~  * Myofascial release of iliopsoas.~  * TENS for 15 minutes.
Study NCT04760366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stretching's of iliopsoas muscle
Description: Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~1. modified lunge position.~2. The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~* Hot pack for 15 minutes.~* Myofascial release of iliopsoas~* TENS for 15 minutes.
Study NCT04760366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the conventional therapy
Description: the conventional therapy
Study NCT04760366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the conventional therapy
Description: the conventional therapy
Study NCT04455321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture materials effect on istmocel
Description: Effect of suture materials with different absorption times on istmocel
Study NCT04455321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture materials effect on istmocel
Description: Effect of suture materials with different absorption times on istmocel
Study NCT02776033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Study NCT02776904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychomotor Vigilance Task
Description: Assessment measuring reaction time based on auditory cues.
Study NCT01590524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Progressive Muscle Relaxation
Description: Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
Study NCT03385395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OctaAlpha1
Description: For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
Study NCT03385395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glassia
Description: For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
Study NCT00807456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
Study NCT01070654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 40/30 recruitment manoeuvre
Description: The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.